<!DOCTYPE HTML>
<!-- template-example-json.html -->

<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
<head>
  <title>Medicinalproductinteraction-example.json - FHIR v3.5.0</title>

  
  <meta name="viewport" content="width=device-width, initial-scale=1.0"/>
  <meta name="author" content="http://hl7.org/fhir"/>

  <link href="fhir.css" rel="stylesheet"/>
  <link rel="Prev" href="http://hl7.org/fhir/medicinalproductinteraction-example.json.html"/>

  <!-- Bootstrap core CSS -->
  <link href="./dist/css/bootstrap.css" rel="stylesheet"/>
  <link href="./assets/css/bootstrap-fhir.css" rel="stylesheet"/>

  <!-- Project extras -->
  <link href="./assets/css/project.css" rel="stylesheet"/>
  <link href="./assets/css/pygments-manni.css" rel="stylesheet"/>
	<link href="jquery-ui.css" rel="stylesheet"/>

  <!-- HTML5 shim and Respond.js IE8 support of HTML5 elements and media queries -->
  <!--[if lt IE 9]>
  <script src="./assets/js/html5shiv.js"></script>
  <script src="./assets/js/respond.min.js"></script>
  <![endif]-->

  <!-- Favicons -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="./assets/ico/apple-touch-icon-144-precomposed.png"/>
  <link rel="apple-touch-icon-precomposed" sizes="114x114" href="./assets/ico/apple-touch-icon-114-precomposed.png"/>
  <link rel="apple-touch-icon-precomposed" sizes="72x72" href="./assets/ico/apple-touch-icon-72-precomposed.png"/>
  <link rel="apple-touch-icon-precomposed" href="./assets/ico/apple-touch-icon-57-precomposed.png"/>
  <link rel="shortcut icon" href="./assets/ico/favicon.png"/>

</head>
<body>
	<div id="segment-header" class="segment"><!-- segment-header -->	
		<div class="container"><!-- container -->
			<a id="logo" href="http://hl7.org/fhir" no-external="true"><img src="./assets/images/fhir-logo-www.png" alt="logo fhir"/> </a>
			<div id="hl7-status">
				<b>Custom NCATS Translator JHU Build</b><br /> <a href="https://ncats.nih.gov"><img src="https://ncats.nih.gov/sites/all/themes/ncats-2014/images/assets/ncats-logo.png" height="50" /></a> <a href="https://www.hopkinsmedicine.org/"><img src="/jhulogo.png" height="100" /></a>
			</div>       	
			
			<div id="hl7-nav">
				 <a id="hl7-logo" href="http://www.hl7.org" no-external="true">
					<img src="./assets/images/hl7-logo.png" width="42" height="50" alt="visit the hl7 website"/>
				</a> 
			</div>       	
			<div id="hl7-nav"><a id="hl7-logo" no-external="true" href="http://hl7.org/fhir/search.cfm"><img alt="Search FHIR" src="./assets/images/search.png"/></a></div> 
		</div>
		<div class="container"><!-- container -->
	</div></div><!-- /segment-header -->	


	<div id="segment-navbar" class="segment"><!-- segment-navbar -->
		<div id="stripe"> </div>
		<div class="container"><!-- container -->
 <!-- HEADER CONTENT -->
 	      		 	      		      		
			<nav class="navbar navbar-inverse">
				<div class="container">
					<button data-target=".navbar-inverse-collapse" data-toggle="collapse" class="navbar-toggle" type="button">
						<span class="icon-bar"> </span>
						<span class="icon-bar"> </span>
						<span class="icon-bar"> </span>
					</button>
					<a href="index.html" class="navbar-brand hidden">FHIR</a>
					<div class="nav-collapse collapse navbar-inverse-collapse">
						<ul class="nav navbar-nav">
              <li><a href="./index.html">Home</a></li>
              <li><a href="./modules.html">Getting Started</a></li>
              <li><a href="./documentation.html">Documentation</a></li>
              <li><a href="./resourcelist.html">Resources</a></li>
              <li><a href="./profilelist.html">Profiles</a></li>
              <li><a href="./extensibility-registry.html">Extensions</a></li>
              <li><a href="./operationslist.html">Operations</a></li>
              <li><a href="./terminologies-systems.html">Terminologies</a></li>
						</ul>
					</div><!-- /.nav-collapse -->
				</div><!-- /.container -->
			</nav><!-- /.navbar -->
      		
<!-- /HEADER CONTENT -->				
		</div><!-- /container -->
	</div><!-- /segment-navbar -->
	

	<div id="segment-breadcrumb" class="segment"><!-- segment-breadcrumb -->
		<div class="container"><!-- container -->	
			<ul class="breadcrumb">
        <li><a href="medications-module.html"><img src="medication.png"/> Medications</a></li>        <li><a href="medicinalproductinteraction.html">MedicinalProductInteraction</a></li>        <li><b>Example Instance</b></li>        <!-- medicinalproductinteraction-example.json.html / resource-instance:MedicinalProductInteraction / Example-->

			</ul>	
		</div><!-- /container -->
	</div><!-- /segment-breadcrumb -->
	

	<div id="segment-content" class="segment"><!-- segment-content -->
	<div class="container"><!-- container -->
            <div class="row">
            	<div class="inner-wrapper">
<!-- CONTENT CONTENT -->


<div class="col-12">

<h1>Medicinalproductinteraction-example.json</h1>
<table class="colsi"><tr><td><a href="http://www.hl7.org/Special/committees/rcrim/index.cfm">Biomedical Research and Regulation</a> Work Group</td><td><a href="versions.html#maturity">Maturity Level</a>: N/A</td><td id="ballot"><a href="ballot-intro.html#process">Ballot Status</a>: Informative</td><!--!ns!--><td><a href="compartmentdefinition.html">Compartments</a>: Not linked to any defined compartments</td></tr></table>

<p>
<a href="medicinalproductinteraction-example.json">Raw JSON</a> (<a href="medicinalproductinteraction-example.canonical.json">canonical form</a> + also see <a href="json.html">JSON Format Specification</a>)
</p>

<div class="example">
<p>Example of medicinalproductinteraction</p>
<pre class="json">
{
  &quot;resourceType&quot;: &quot;MedicinalProductClinicals&quot;,
  &quot;id&quot;: &quot;example&quot;,
  &quot;text&quot;: {
    &quot;status&quot;: &quot;generated&quot;,
    &quot;div&quot;: &quot;&lt;div xmlns=\&quot;http://www.w3.org/1999/xhtml\&quot;&gt;&lt;p&gt;&lt;b&gt;Generated Narrative with Details&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;id&lt;/b&gt;: example&lt;/p&gt;&lt;h3&gt;UndesirableEffects&lt;/h3&gt;&lt;table&gt;&lt;tr&gt;&lt;td&gt;-&lt;/td&gt;&lt;td&gt;&lt;b&gt;SymptomConditionEffect&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;Classification&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;FrequencyOfOccurrence&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;*&lt;/td&gt;&lt;td&gt;Prevention of\\nVTE in adult\\npatients who have\\nundergone\\nelective hip or\\nknee replacement\\nsurgery (VTEp) &lt;span&gt;(Details : {http://ema.europa.eu/example/undesirableeffectassymptom-condition-effect code 'Anaemia' = 'Anaemia)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;Bloodandlymphaticsystemdisorders &lt;span&gt;(Details : {http://ema.europa.eu/example/symptom-condition-effectclassification code 'Bloodandlymphaticsystemdisorders' = 'Bloodandlymphaticsystemdisorders)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;Common &lt;span&gt;(Details : {http://ema.europa.eu/example/frequencyofoccurrence code 'Common' = 'Common)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;blockquote&gt;&lt;p&gt;&lt;b&gt;therapeuticIndication&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;diseaseSymptomProcedure&lt;/b&gt;: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip\\nor knee replacement surgery.\\nPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation\\n(NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age\\n≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).\\nTreatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent\\nDVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). &lt;span&gt;(Details : {http://ema.europa.eu/example/indicationasdisease-symptom-procedure code 'Venousthromboembolismprophylaxis' = 'Venousthromboembolismprophylaxis)&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;comorbidity&lt;/b&gt;: Hipsurgery &lt;span&gt;(Details : {http://ema.europa.eu/example/comorbidity code 'Hipsurgery' = 'Hipsurgery)&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;intendedEffect&lt;/b&gt;: PRYLX &lt;span&gt;(Details : {http://ema.europa.eu/example/intendedeffect code 'PRYLX' = 'PRYLX)&lt;/span&gt;&lt;/p&gt;&lt;h3&gt;Populations&lt;/h3&gt;&lt;table&gt;&lt;tr&gt;&lt;td&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;*&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/blockquote&gt;&lt;h3&gt;Contraindications&lt;/h3&gt;&lt;table&gt;&lt;tr&gt;&lt;td&gt;-&lt;/td&gt;&lt;td&gt;&lt;b&gt;Disease&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;Comorbidity&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;*&lt;/td&gt;&lt;td&gt;Hepatic disease associated with coagulopathy and clinically relevant bleeding risk &lt;span&gt;(Details : {http://ema.europa.eu/example/contraindicationsasdisease-symptom-procedure code 'Coagulopathiesandbleedingdiatheses(exclthrombocytopenic)' = 'Coagulopathiesandbleedingdiatheses(exclthrombocytopenic))&lt;/span&gt;&lt;/td&gt;&lt;td&gt;Hepaticdisease &lt;span&gt;(Details : {http://ema.europa.eu/example/comorbidity code 'Hepaticdisease' = 'Hepaticdisease)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3&gt;Interactions&lt;/h3&gt;&lt;table&gt;&lt;tr&gt;&lt;td&gt;-&lt;/td&gt;&lt;td&gt;&lt;b&gt;Interaction&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;Interactant&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;Type&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;Effect&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;Management&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;*&lt;/td&gt;&lt;td&gt;Inhibitors of CYP3A4 and P-gp\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\nequixaban Cmax.\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\nsection 4.4).\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.&lt;/td&gt;&lt;td&gt;ketoconazole &lt;span&gt;(Details : {http://ema.europa.eu/example/interactant code 'ketoconazole' = 'ketoconazole)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;StrongInhibitorofCYP3A4 &lt;span&gt;(Details : {http://ema.europa.eu/example/interactionsType code 'StrongInhibitorofCYP3A4' = 'StrongInhibitorofCYP3A4)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;Increasedplasmaconcentrations &lt;span&gt;(Details : {http://ema.europa.eu/example/interactionseffect code 'Increasedplasmaconcentrations' = 'Increasedplasmaconcentrations)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;CoadministrationnotrecommendedinpatientsreceivingconcomitantsystemictreatmentstronginhibitorsofbothCYP3A4andP-gp &lt;span&gt;(Details : {http://ema.europa.eu/example/managementactions code 'CoadministrationnotrecommendedinpatientsreceivingconcomitantsystemictreatmentstronginhibitorsofbothCYP3A4andP-gp' = 'CoadministrationnotrecommendedinpatientsreceivingconcomitantsystemictreatmentstronginhibitorsofbothCYP3A4andP-gp)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&quot;
  },
  &quot;undesirableEffects&quot;: [
    {
      &quot;symptomConditionEffect&quot;: {
        &quot;coding&quot;: [
          {
            &quot;system&quot;: &quot;http://ema.europa.eu/example/undesirableeffectassymptom-condition-effect&quot;,
            &quot;code&quot;: &quot;Anaemia&quot;
          }
        ],
        &quot;text&quot;: &quot;Prevention of\\nVTE in adult\\npatients who have\\nundergone\\nelective hip or\\nknee replacement\\nsurgery (VTEp)&quot;
      },
      &quot;classification&quot;: {
        &quot;coding&quot;: [
          {
            &quot;system&quot;: &quot;http://ema.europa.eu/example/symptom-condition-effectclassification&quot;,
            &quot;code&quot;: &quot;Bloodandlymphaticsystemdisorders&quot;
          }
        ]
      },
      &quot;frequencyOfOccurrence&quot;: {
        &quot;coding&quot;: [
          {
            &quot;system&quot;: &quot;http://ema.europa.eu/example/frequencyofoccurrence&quot;,
            &quot;code&quot;: &quot;Common&quot;
          }
        ]
      }
    }
  ],
  &quot;therapeuticIndication&quot;: [
    {
      &quot;diseaseSymptomProcedure&quot;: {
        &quot;coding&quot;: [
          {
            &quot;system&quot;: &quot;http://ema.europa.eu/example/indicationasdisease-symptom-procedure&quot;,
            &quot;code&quot;: &quot;Venousthromboembolismprophylaxis&quot;
          }
        ],
        &quot;text&quot;: &quot;Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip\\nor knee replacement surgery.\\nPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation\\n(NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age\\n≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).\\nTreatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent\\nDVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).&quot;
      },
      &quot;comorbidity&quot;: [
        {
          &quot;coding&quot;: [
            {
              &quot;system&quot;: &quot;http://ema.europa.eu/example/comorbidity&quot;,
              &quot;code&quot;: &quot;Hipsurgery&quot;
            }
          ]
        }
      ],
      &quot;intendedEffect&quot;: {
        &quot;coding&quot;: [
          {
            &quot;system&quot;: &quot;http://ema.europa.eu/example/intendedeffect&quot;,
            &quot;code&quot;: &quot;PRYLX&quot;
          }
        ]
      },
      &quot;population&quot;: [
        {
          &quot;ageRange&quot;: {
            &quot;low&quot;: {
              &quot;value&quot;: 18,
              &quot;unit&quot;: &quot;a&quot;
            }
          }
        }
      ]
    }
  ],
  &quot;contraindication&quot;: [
    {
      &quot;disease&quot;: {
        &quot;coding&quot;: [
          {
            &quot;system&quot;: &quot;http://ema.europa.eu/example/contraindicationsasdisease-symptom-procedure&quot;,
            &quot;code&quot;: &quot;Coagulopathiesandbleedingdiatheses(exclthrombocytopenic)&quot;
          }
        ],
        &quot;text&quot;: &quot;Hepatic disease associated with coagulopathy and clinically relevant bleeding risk&quot;
      },
      &quot;comorbidity&quot;: [
        {
          &quot;coding&quot;: [
            {
              &quot;system&quot;: &quot;http://ema.europa.eu/example/comorbidity&quot;,
              &quot;code&quot;: &quot;Hepaticdisease&quot;
            }
          ]
        }
      ]
    }
  ],
  &quot;interactions&quot;: [
    {
      &quot;interaction&quot;: &quot;Inhibitors of CYP3A4 and P-gp\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\nequixaban Cmax.\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\nsection 4.4).\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.&quot;,
      &quot;interactant&quot;: [
        {
          &quot;coding&quot;: [
            {
              &quot;system&quot;: &quot;http://ema.europa.eu/example/interactant&quot;,
              &quot;code&quot;: &quot;ketoconazole&quot;
            }
          ]
        },
        {
          &quot;coding&quot;: [
            {
              &quot;system&quot;: &quot;http://ema.europa.eu/example/interactant&quot;,
              &quot;code&quot;: &quot;itraconazole&quot;
            }
          ]
        }
      ],
      &quot;type&quot;: {
        &quot;coding&quot;: [
          {
            &quot;system&quot;: &quot;http://ema.europa.eu/example/interactionsType&quot;,
            &quot;code&quot;: &quot;StrongInhibitorofCYP3A4&quot;
          }
        ]
      },
      &quot;effect&quot;: {
        &quot;coding&quot;: [
          {
            &quot;system&quot;: &quot;http://ema.europa.eu/example/interactionseffect&quot;,
            &quot;code&quot;: &quot;Increasedplasmaconcentrations&quot;
          }
        ]
      },
      &quot;management&quot;: {
        &quot;coding&quot;: [
          {
            &quot;system&quot;: &quot;http://ema.europa.eu/example/managementactions&quot;,
            &quot;code&quot;: &quot;CoadministrationnotrecommendedinpatientsreceivingconcomitantsystemictreatmentstronginhibitorsofbothCYP3A4andP-gp&quot;
          }
        ]
      }
    }
  ]
}
</pre>
</div>


<p>
Usage note: every effort has been made to ensure that the
examples are correct and useful, but they are not a normative part 
of the specification. 
</p>

</div>


				</div><!-- /inner-wrapper -->
            </div><!-- /row -->
        </div><!-- /container -->
        
    </div><!-- /segment-content -->


	<div id="segment-footer" class="segment"><!-- segment-footer -->
		<div class="container"><!-- container -->
			<div class="inner-wrapper">
				<p>
        &reg;© HL7.org 2011+. FHIR Release 4 Candidate (v3.5.0-????) generated on Fri, Sep 14, 2018 07:27-0500. <a  style="color: #ffffff" href="qa.html">QA Page</a>
        <br/>
        <span style="color: #FFFF77">
        Links: <a style="color: #b8dcf9" href="http://hl7.org/fhir/search.cfm">Search</a> | 
               <a style="color: #b8dcf9" href="history.html">Version History</a> | 
               <a style="color: #b8dcf9" href="toc.html">Table of Contents</a> | 
               <a style="color: #b8dcf9" href="credits.html">Credits</a> | 
               <a style="color: #b8dcf9" href="http://services.w3.org/htmldiff?doc1=http%3A%2F%2Fhl7.org%2Ffhir%2FSTU3%2Fmedicinalproductinteraction-example.json.html&amp;doc2=http%3A%2F%2Fbuild.fhir.org%2Fmedicinalproductinteraction-example.json.html">Compare to DSTU3</a> |                
               <a style="color: #b8dcf9" href="http://services.w3.org/htmldiff?doc1=http%3A%2F%2Fhl7.org%2Ffhir%2F2018May%2Fmedicinalproductinteraction-example.json.html&amp;doc2=http%3A%2F%2Fbuild.fhir.org%2Fmedicinalproductinteraction-example.json.html">Ballot Comparison</a> |                
               <a style="color: #b8dcf9" rel="license" href="license.html"><img src="cc0.png" style="border-style: none;" alt="CC0"/></a> | 
               <a style="color: #b8dcf9" target="_blank" href="http://gforge.hl7.org/gf/project/fhir/tracker/?action=TrackerItemAdd&amp;tracker_id=677">Propose a change</a>   
        </span>
        </p>
			</div><!-- /inner-wrapper -->
		</div><!-- /container -->
	</div><!-- /segment-footer -->
<!-- disqus thread -->
<!--disqus-->
<!-- end disqus -->        
	
	<div id="segment-post-footer" class="segment hidden"><!-- segment-post-footer -->
		<div class="container"><!-- container -->
		</div><!-- /container -->
	</div><!-- /segment-post-footer -->
    
    <!-- JS and analytics only. -->
    <!-- Bootstrap core JavaScript
================================================== -->
<!-- Placed at the end of the document so the pages load faster -->
<script src="./assets/js/jquery.js"> </script>   <!-- note keep space here, otherwise it will be transformed to empty tag -> fails -->
<script src="./dist/js/bootstrap.min.js"> </script>
<script src="./assets/js/respond.min.js"> </script>

<script src="./assets/js/fhir.js"> </script>

<!-- Analytics Below
================================================== -->

    
</body>
</html>
